



DATE: January 5, 2024

**TO:** Commonwealth of Kentucky Medicaid Pharmacy Network

FROM: MedImpact Healthcare Systems

**Subject: Generic Fluticasone HFA Moving to Preferred PDL Status** 

On December 31<sup>st</sup>, 2023, GlaxoSmithKline (GSK) has discontinued all strengths of Flovent HFA and Flovent Diskus. Supply is expected to diminish across the United States during the first quarter of 2024.

In an effort to minimize therapy disruptions for patients as well as the provider community, generic Fluticasone HFA inhalers will be moving to preferred status in the Glucocorticoids, Inhaled PDL class. This change will be effective on **Friday January 5**, **2024**.

## **KY MCO Contact Information**

Program Questions	KYMCOPBM@MedImpact.com
Pharmacy Help Desk	(800) 210-7628 [24 hours per day/ 7 days per week]
Prior Authorizations	Phone (844) 336-2676 [8:00AM - 7:00PM EST/ 7 days per week];Fax (858) 357-2612
Pharmacy Portal	https://kyportal.medimpact.com/
BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01	

## **KY FFS Contact Information**

Program Questions	KYMFFS@MedImpact.com
Pharmacy Help Desk	(877) 403-6034 [24 hours per day/ 7 days per week]
Prior Authorizations	Phone (877) 403-6034 [8:00AM - 7:00PM EST/ 7 days per week]
	Fax (858) 357-2612
Pharmacy Portal	https://kyportal.medimpact.com/
BIN: 026309 / PCN: KYPROD1 / GROUP: KYF01	

